findmyKOL

Huifang Lu, MD, PhD

Basic profile

The University of Texas MD Anderson Cancer Center

ORCIDNPI
RegionHouston, TX · South CentralSpecialtyRheumatologyFocusRheumatology/Immunology
Last active 1999findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPaymentsNone reportedNIH funding1997–1999Why? →

Huifang Lu is a Rheumatology/Immunology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 85 publications with 2,888 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
85publications

Distinct works indexed by OpenAlex, matched via ORCID.

2,888citations

Total citations across indexed works.

21h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials
1NIH grants · 1997–1999

Federally funded research awards.

View funding

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    45.1%
    Corticosteroid35.6%
    Prednisone100%
    Part D26 patients
    Aminosalicylate9.4%
    Sulfasalazine100%
    Part D<11 patients
  • Cancer & immunology

    24.5%
    Folate Analog Metabolic Inhibitor18.5%
    Methotrexate100%
    Part D<11 patients
    Interleukin-6 Receptor Antagonist6%
    Actemra100%
    Part D<11 patients
  • Antiparasitic

    16.7%
    Antimalarial16.7%
    Hydroxychloroquine Sulfate100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 19971999 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”